Novo Nordisk and OpenAI Partner to Speed Drug Discovery
By Dominic Chopping
Novo Nordisk and OpenAI will work together as they seek to harness artificial intelligence to discover new drugs and improve efficiency.
The strategic partnership announced Tuesday will integrate OpenAI's advanced AI capabilities throughout the drugmaker's operations, helping employees to analyze data and identify new drug candidates.
"Integrating AI in our everyday work gives us the ability to analyse datasets at a scale that was previously impossible, identify patterns we could not see, and test hypotheses faster than ever," Novo Nordisk Chief Executive Mike Doustdar said.
"This means discovering new therapies and bringing them to market faster than ever before."
The partnership will also apply OpenAI's capabilities to improve efficiency in manufacturing, supply chain and distribution and corporate operations.
Pilot programs will launch across research and development, manufacturing and commercial operations, with full integration by the end of 2026.
"This collaboration with Novo Nordisk will help them accelerate scientific discovery, run smarter global operations, and redefine the future of patient care," said OpenAI Chief Executive Sam Altman.
Financial terms weren't disclosed.
Write to Dominic Chopping at dominic.chopping@wsj.com
(END) Dow Jones Newswires
April 14, 2026 02:45 ET (06:45 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
Why This Vanguard ETF Is One of the Best
6 ETFs To Diversify Away From AI
The Best AI Stocks to Buy Now
United States